Should Obesity Medications Be Covered?
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Should Obesity Medications Be Covered?
-
Lu par :
-
De :
À propos de ce contenu audio
Obesity is a chronic disease that accounts for over 80% of the risk of developing Type 2 diabetes. Equally important, it can also lead to high blood pressure, a common cause of heart attacks. But today, there is good news. There are many anti-obesity medications such as Hollywood favourite Ozempic or Wegovy that can impact appetite and fullness. The issue is that these medications are usually quite expensive and often not covered by Group Benefits plans.
In this short podcast, Allison Brown, VP Consulting at Thorpe Benefits and Roger Thorpe discuss how covering these medications may help employers in the long run by reducing absenteeism and health risks while improving productivity.
Aucun commentaire pour le moment
